Cargando…
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry
BACKGROUND: The Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry investigated the safety and efficacy of the factor Xa inhibitor rivaroxaban. We studied the Dutch XANTUS cohort to a ssess drug safety and prescription patterns in the Netherlands. METHODS: The XA...
Autores principales: | Pisters, R., van Vugt, S. P. G., Brouwer, M. A., Elvan, A., ten Holt, W. L., Zwart, P. A. G., Kirchhof, P., Crijns, H. J. G. M., Hemels, M. E. W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612862/ https://www.ncbi.nlm.nih.gov/pubmed/28674871 http://dx.doi.org/10.1007/s12471-017-1009-9 |
Ejemplares similares
-
Optimal long-term antithrombotic management of atrial fibrillation: life cycle management
por: Pisters, R., et al.
Publicado: (2018) -
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
por: Camm, A. John, et al.
Publicado: (2020) -
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014) -
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016) -
A Medwatch review of reported events in patients who discontinued rivaroxaban (XARELTO) therapy in response to legal advertising
por: Burton, Paul, et al.
Publicado: (2016)